Authors' reply

The Lancet

Volumn 381, Issue 9877, 2013, Pages 1538-1539

  Van Cutsem, Eric ^a   Grothey, Axel ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

REGORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; METASTATIC COLORECTAL CANCER; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TREATMENT RESPONSE; COLORECTAL TUMOR; FEMALE; MALE; NOTE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84877275135     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60978-2     Document Type: Letter

References (2)

1. A Grothey, E Van Cutsem, A Sobrero et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
2. A Grothey, E Van Cutsem, A Sobrero et al. Time course of regorafenib-associated adverse events in the phase III CORRECT study Proc Am Soc Clin Oncol 30 suppl 34 2012 467 (abstr).